BiotechTube

AVXS-101

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinal Muscular Atrophy 1

Conditions

Spinal Muscular Atrophy 1

Trial Timeline

May 5, 2014 → Dec 15, 2017

NCT ID
NCT02122952

About AVXS-101

AVXS-101 is a phase 1 stage product being developed by Novartis for Spinal Muscular Atrophy 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02122952. Target conditions include Spinal Muscular Atrophy 1.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02122952Phase 1Completed

Competing Products

20 competing products in Spinal Muscular Atrophy 1

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
52
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
52
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
33
ElezanumabAbbViePre-clinical
23
Elezanumab + PlaceboAbbViePhase 2
52
Ropivacaine + BupivacaineAstraZenecaPhase 3
77
Onasemnogene Abeparvovec-xioiNovartisPhase 1
33
ZolgensmaNovartisPre-clinical
23
BVS857 + PlaceboNovartisPhase 2
52
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
Onasemnogene Abeparvovec-brveNovartisApproved
85
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
23
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
branaplamNovartisPhase 1/2
41
Onasemnogene Abeparvovec-xioiNovartisPhase 3
77
onasemnogene abeparvovecNovartisPhase 3
77
onasemnogene abeparvovec-xioiNovartisPhase 3
77
RisdiplamRochePhase 1
33
ATI355NovartisPhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85